Sugi Predict

Sugi Predict / Compounds / SCHEMBL17446604

SCHEMBL17446604

SCHEMBL17446604

CC(C)NCCCCCC(=O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.42
▸ FAAH O00519 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ EPHX1 P07099 1/20 0.40
▸ CES2 O00748 1/20 0.36
▸ ADRA1A P35348 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13884348 1.00 MEN1 (0.42) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL25109878 1.00 MEN1 (0.42) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL26700639 1.00 MEN1 (0.42) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL20332107 1.00 MEN1 (0.42) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL12438086 0.98 MEN1 (0.39) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL10110753 0.91 MEN1 (0.36) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL19654104 0.89 CASP2 (0.44) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL25483586 0.84 MEN1 (0.36) MEN1FAAHMAPK1KMT2AEPHX1
SCHEMBL18592280 0.83 KDM4E (0.37) MEN1KMT2AKDM4EALDH1A1HRH3
SCHEMBL22305756 0.82 KDM4E (0.43) MEN1FAAHMAPK1KMT2AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024089405-A2 INSECT NEUROPEPTIDE ANALOGUES Solasta Bio Limited (GB) 2024-05-02 — — WO disclosed
US-11840691-B2 Compound and application thereof KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) 2023-12-12 — — US disclosed
US-20230374513-A1 NOVEL COMPOUND AND APPLICATION THEREOF KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) 2023-11-23 — — US disclosed
US-20230158150-A1 COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF NOVARTIS AG (CH) 2023-05-25 — — US disclosed
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230144322-A1 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS CANCER TARGETED TECHNOLOGY, LLC 2023-05-11 — — US disclosed
US-20230144322-A1 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS CANCER TARGETED TECHNOLOGY, LLC 2023-05-11 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
WO-2021113524-A2 GLP2 RECEPTOR AGONISTS AND METHODS OF USE THE SCRIPPS RESEARCH INSTITUTE (US) 2021-06-10 — — WO disclosed
US-20210121585-A1 PSMA targeted radiotherapy medicine and preparation method thereof LI MING HSIN (TW) 2021-04-29 — — US disclosed
US-20170209591-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMACEUTICALS, INC. 2017-07-27 — — US disclosed
US-9382540-B2 Compositions and methods for modulating angiopoietin-like 3 expression ISIS PHARMACEUTICALS, INC (US) 2016-07-05 — — US disclosed
US-20160082112-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-24 — — US disclosed
US-20160030605-A1 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-04 — — US disclosed
US-20160017323-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144322-A1 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS FOLH1, PSMA2, PSMA6 MEN1 129/4885FAAH 62/4885MAPK1 2968/4885
US-20160082112-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER CD47, FCGR1A, FCGR2A MEN1 671/4885FAAH 4368/4885MAPK1 3578/4885
US-20230374513-A1 NOVEL COMPOUND AND APPLICATION THEREOF GALNT6, GALNT3, GALNT14 MEN1 4246/4885FAAH 4663/4885MAPK1 2844/4885
US-20160030605-A1 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS FOLH1, PSMA2, PSMA6 MEN1 129/4885FAAH 62/4885MAPK1 2968/4885
US-20170209591-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE HNMT, SLC10A1, SLC10A2 MEN1 843/4885FAAH 2231/4885MAPK1 2734/4885
US-20230158150-A1 COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF NSUN2, NSUN3, POLM MEN1 1278/4885FAAH 3897/4885MAPK1 4299/4885
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 MEN1 1517/4885FAAH 3355/4885MAPK1 2338/4885
US-11840691-B2 Compound and application thereof GALNT6, GALNT3, GALNT14 MEN1 4080/4885FAAH 4700/4885MAPK1 2679/4885
US-20210121585-A1 PSMA targeted radiotherapy medicine and preparation method thereof FOLH1, KLK3, PSMA1 MEN1 396/4885FAAH 3922/4885MAPK1 2048/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 MEN1 1348/4885FAAH 3195/4885MAPK1 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.